Resverlogix Corp
Company Profile
Business description
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Contact
4820 Richard Road SW
Suite 300
CalgaryABT3E 6L1
CANT: +1 403 254-9252
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
17
Stocks News & Analysis
stocks
ASX payments utility looks overvalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,823.20 | 71.40 | -0.80% |
| CAC 40 | 7,729.69 | 39.52 | -0.51% |
| DAX 40 | 24,806.97 | 297.39 | -1.18% |
| Dow JONES (US) | 51,231.64 | 51.77 | 0.10% |
| FTSE 100 | 10,441.60 | 16.90 | -0.16% |
| HKSE | 23,785.79 | 344.71 | -1.43% |
| NASDAQ | 27,193.34 | 345.35 | -1.25% |
| Nikkei 225 | 69,042.11 | 993.60 | -1.42% |
| NZX 50 Index | 13,691.85 | 7.81 | 0.06% |
| S&P 500 | 7,765.36 | 36.41 | -0.47% |
| S&P/ASX 200 | 8,660.90 | 66.80 | -0.77% |
| SSE Composite Index | 3,811.90 | 30.29 | -0.79% |